Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).

An international, Phase III clinical trial led by investigators at Mass General Brigham could improve the treatment of a rare ...